Genetically-modified hematopoietic stem cells and their progeny for widespread and efficient protein delivery to diseased sites: The case of lysosomal storage disorders

Alessandra Biffi

Research output: Contribution to journalArticle

Abstract

Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.

Original languageEnglish
Pages (from-to)381-388
Number of pages8
JournalCurrent Gene Therapy
Volume12
Issue number5
DOIs
Publication statusPublished - 2012

Fingerprint

Hematopoietic Stem Cells
Brain
Intravenous Administration
Proteins
Injections
Therapeutics

Keywords

  • Central nervous system
  • Gene therapy
  • Hematopoietic stem cells

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

@article{07a3f8b758454ced99457206c5468f44,
title = "Genetically-modified hematopoietic stem cells and their progeny for widespread and efficient protein delivery to diseased sites: The case of lysosomal storage disorders",
abstract = "Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.",
keywords = "Central nervous system, Gene therapy, Hematopoietic stem cells",
author = "Alessandra Biffi",
year = "2012",
doi = "10.2174/156652312802762572",
language = "English",
volume = "12",
pages = "381--388",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Genetically-modified hematopoietic stem cells and their progeny for widespread and efficient protein delivery to diseased sites

T2 - The case of lysosomal storage disorders

AU - Biffi, Alessandra

PY - 2012

Y1 - 2012

N2 - Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.

AB - Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.

KW - Central nervous system

KW - Gene therapy

KW - Hematopoietic stem cells

UR - http://www.scopus.com/inward/record.url?scp=84867000502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867000502&partnerID=8YFLogxK

U2 - 10.2174/156652312802762572

DO - 10.2174/156652312802762572

M3 - Article

C2 - 22934618

AN - SCOPUS:84867000502

VL - 12

SP - 381

EP - 388

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 5

ER -